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Abstract: Vulvovaginal atrophy [VVA] is defined as inflammation of the vaginal epithelium 
due to atrophy secondary to decreased levels of circulating estrogen. There is currently only 
one approved method for the treatment of VVA, and that is the administration of exogenous 
estrogens. Overall, the ideal VVA treatment must have benefits, minimize risks, and enhance 
compliance in the patient while optimizing cost-effectiveness. Unfortunately, of the approxi-
mate 25% of symptomatic women that are thought to seek medical help, the proportion that 
receives hormone therapy may be small and its duration of use is short. Women have been very 
reluctant to take hormone therapy due to widely publicized results of the risks associated with 
hormone therapy. Thus, while menopausal hormone therapy was once accepted as the ideal 
approach for optimizing changes associated with menopause, prospective randomized clinical 
trials have challenged that view and have led to a marked decrease in the use of such therapy 
and increased search for low-dose therapies. This article will highlight the efficacy and safety 
of recently FDA-approved Vagifem (10 mcg) in treatment of VVA.
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Introduction
As endogenous estrogen serum levels decline during menopause, the genital tract 
and other estrogen-dependent tissues gradually undergo atrophic changes. VVA is 
a thinning of the epithelium secondary to decreased levels of circulating estrogen. 
Changes in cytology can occur with decreased estrogen levels, leading to increased 
intermediate and parabasal cells in relation to superficial cells. The loss in estrogen-
dependent   cellular maturation in the vagina can result in VVA. The affected tissue 
becomes more friable, and petechiae, ulcerations, and bleeding may occur after 
  minimal trauma. Blood flow to the vagina is also reduced, leading to a decrease in the 
transudation, which normally lubricates the vagina during sexual intimacy, resulting 
in dryness and dyspareunia. The symptoms of VVA are not limited to the menopausal 
population; symptoms can start before perimenopause, increase during the early 
perimenopausal period, and further increase in the 2–3 years after menopause. VVA 
symptoms range in severity from mildly annoying to unbearable. It is progressive 
and does not spontaneously resolve. Thus, long-term therapy may be necessary to 
maintain urogenital health.
Currently, women spend more than one-third of their lives in the estrogen-deficient 
menopausal state. In 2008, there were 50 million American women 50 years or 
older, and this segment of the population is expected to grow to about 85 million by 
the year 2014.1 According to the North American Menopause Society (NAMS), an 
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estimated 10%–40% of menopausal women will experience 
  symptoms related to VVA.2 That translates into approxi-
mately 16   million women, including 500,000 new patients 
per year presenting with symptoms of VVA.
Present hormone therapies approved for this condition 
are administered either systemically or locally in the vagina. 
The FDA recommends that vaginal formulations are the 
first choice for the initial management of VVA symptoms. 
Current recommendations are to continue use of local estro-
gen therapy for as long as necessary for symptom control. 
A retrospective study conducted in .13,000 women showed 
that the duration of local estrogen therapy in the real-life set-
ting is about 12 months.3 Notwithstanding the above, there 
seems to be a growing satisfaction among both patients 
and clinicians with the use of HT to effectively treat VVA. 
Today, local treatments available to clinicians for VVA are 
in the form of creams, tablets, and a vaginal ring. Leading 
estrogens Premarin cream, Estrace, Estring, and Femring are 
examples (Table 1). These products generally work well and 
are believed to be safe to use even though vaginal formula-
tions have not been tested in long-term trials to support an 
assumed more favorable risk–benefit ratio.
Another option for local estrogen therapy is the estradiol 
vaginal tablet. The tablet containing 25 mcg 17b-Estradiol 
(Vagifem® Novo Nordisk) was first introduced in 1988 and 
has been shown to provide continuous release of the steroid 
with transient absorption being significantly reduced after 
maturation of the epithelium.4 The estradiol vaginal tablet 
can be administered in the vagina through a hydrophilic 
cellulose-based slow-release tablet.5 One tablet is inserted in 
the vagina once daily for the first 2 weeks, then twice a week 
thereafter for the purpose of maintenance therapy. Once the 
tablet comes in contact with vaginal mucosa, a gel layer is 
formed, allowing diffusion of estradiol.
In general, when compared with vaginal estrogen 
creams or suppositories, tablets provide a more consistent 
dose of the hormone, reduce potential leakage, and are 
associated with greater patient adherence.6,7 All treat-
ments provided equivalent relief of the symptoms of VVA 
based on composite scores of vaginal symptoms (dryness, 
  soreness, and   irritation). At weeks 2, 12, and 24, increases in 
serum   estradiol concentrations and suppression of follicle-
  stimulating   hormone (FSH) were observed in significantly 
more patients who were using the vaginal cream than in those 
using the vaginal tablet (25 mcg) (P , 0.001).   Further, a 
retrospective study of patient adherence to vaginal estrogen 
therapy found that those prescribed vaginal creams dis-
continued treatment sooner than those given tablets (50% 
discontinuance at 30 days with cream and at 142 days with 
the tablet; P , 0.001) and filled fewer prescriptions. Better 
adherence with the tablets occurred despite higher out-of-
pocket costs for vaginal tablets.
Efficacy
Studies with the 25 mcg estradiol vaginal tablet showed 
significant improvement in VVA symptoms. In a double-
blind, placebo-controlled study, 1612 menopausal patients 
with urogenital complaints were randomized to receive the 
Vagifem insert (25 mcg) or placebo tablet once a day for a 
period of 2 weeks, and then twice a week for a total of the 
12 months.8 The success rates of Vagifem vs placebo on 
subjective and objective symptoms of VVA were 85.5% and 
41.4%, respectively. A significant improvement of urinary 
atrophy symptoms was also seen in the Vagifem-treated 
group as compared with the beginning of the study (51.9% 
vs 15.5%, P = 0.001). It was initially thought that the 25 mcg 
dose would be necessary for the effective treatment of VVA. 
In recent years, there has been an effort to use ultra-low-dose 
vaginal formulations to meet therapeutic goals, as an alterna-
tive to traditional regimens.
There were initial findings from clinical trials that a 
lower-dose tablet containing 10 mcg may also be effective 
for the relief of VVA symptoms. In a double-blind, random-
ized, parallel-group study, 58 menopausal women were 
treated with 25 mcg or 10 mcg estradiol vaginal tablet for 
12 weeks.9 In each treatment group, participants demon-
strated significant improvement in vaginal maturation values 
over baseline at weeks 1 and 2 (P , 0.001), and at week 
12 (P , 0.01). At all points, mean maturation values were 
comparable between groups.
Table 1 Current hormonal therapies for vulvovaginal atrophy
Drug name Drug category Form and delivery Dosage Pharmaceutical company
Premarin vaginal cream® Estrogen derivative Vaginal cream 0.625 mg conjugated estrogens Wyeth
Estrace® Estrogen derivative Vaginal cream 0.01% estradiol cream Warner Chilcott
Estring® Estrogen derivative Vaginal ring 7.5 mcg 17β estradiol Pfizer
*Femring® Estrogen derivative Vaginal ring 0.05 mg or 0.1 mg estradiol Warner Chilcott
Note: *Femring® is FDA-approved for both local and systemic hormone therapy.
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In a multi-center, randomized, double-blind, parallel-
group study, 230 menopausal women received treatment 
with 25 mcg or 10 mcg vaginal tablet estradiol or placebo 
for 12 weeks.10 After 12 weeks, the percentage of partici-
pants with pH , 5 were 51%, 39%, and 21% in the 25 mcg, 
10 mcg, and placebo group, respectively. The vaginal 
  cytology results showed significant increases at week 2 and 
7 in the percentage of superficial cells for participants in the 
25 mcg group as compared to placebo. Maturation values 
for the 10 mcg group were significantly higher than for the 
placebo at week 2 (P , 0.001) and were not significantly 
different from the improved values for the 25 mcg group 
at any time point. Vaginal tablets with 25 mcg and 10 mcg 
improved VVA by decreasing vaginal pH and increasing 
maturation of the vaginal epithelium. These improvements 
were greater with the 25 mcg than with the 10 mcg which 
was to be expected.
In a pivotal phase, menopausal women (N = 309) were 
randomly assigned to the 10 mcg estradiol vaginal tablet or 
placebo for 52 weeks in a double-blind study.11 At 12 weeks, 
the change from baseline for 10 mcg compared with placebo 
showed a significant improvement in superficial cells (13.2% 
vs 3.8%, P , 0.001), decreasing the percentage of parabasal 
cells (−37.0% vs −93%, P , 0.001), decreasing vaginal pH 
score (−1.3 vs −0.4, P , 0.001), and most bothersome symp-
tom score (−1.23 vs −0.87, P = 0.003). Also, for percentage 
improvement in the superficial cells and vaginal pH, treat-
ment effects were statistically different from placebo after 
2 weeks of treatment. However, for the most bothersome 
symptoms, treatment effect became apparent after 4 weeks 
and reached statistical significance at 8 weeks of therapy. 
All treatment effects continued to be significant up through 
52 weeks of treatment.
Safety
The endometrial safety of the 10 mcg estradiol vaginal   tablet 
was evaluated in 336 women. The baseline endometrial thick-
ness was 2.04 mm as determined by ultrasound compared 
with 1.94 mm after 52 weeks. There was no evidence of 
increased endometrial thickness after 1 year of treatment 
for VVA in menopausal women.12 In an additional safety 
study, endometrial biopsy data from participants using the 
10 mcg estradiol vaginal tablet (N = 205) in a randomized, 
double-blind, placebo-controlled trial were pooled with the 
data from an open-label endometrial safety trial (N = 336).13 
Patients received active treatment for 52 weeks. A total of 
443 participants had an endometrial biopsy performed at 
week 52. In total, two events of hyperplasia and carcinoma 
were reported in 386 evaluable biopsy samples (incidence 
rate 0.52% per year). The reported prior incidence rate of 
  endometrial hyperplasia and carcinoma in menopausal women 
is 0%–1%. These results were well within the   confidence 
interval bounds established by the FDA   (one-sided 95% con-
fidence interval: 0%–1.62%, upper bound below the 4% rate) 
and the European Medicines Agency (two-sided 95% confi-
dence interval: 0.06%–1.86%, upper bound below 2% rate) 
for endometrial safety. The author concluded that there was 
no increased risk of endometrial hyperplasia or carcinoma in 
menopausal women undergoing treatment for VVA with the 
10 mcg estradiol vaginal tablet after 1 year of therapy.
Other safety events reported in 5% or more of women 
treated with estradiol 10 mcg vaginal tablet for 1 year 
included back pain (7% vs 2% for placebo), diarrhea (5% 
vs 0%), vulvovaginal mycotic infection (8% vs 3%), and 
vulvovaginal pruritus (8% vs 2%).
Vaginal estradiol tablet provides localized effects without 
significant systemic absorption. In a double-blind, random-
ized, parallel-group study, 58 menopausal women were 
treated with 25 mcg or 10 mcg estradiol vaginal tablet for 
12 weeks. Systemic absorption of estradiol was noted to be 
low and stable over time.14 Furthermore, in another assess-
ment, during 12 weeks administration, 10 mcg vaginal tablets 
resulted in at least 50% lower mean estradiol concentrations 
than with the 25 mcg dose within 24 hours after dosing.15 
After administering the 25 mcg dose, mean estradiol levels 
during the first 2 weeks exceeded the published referenced 
range for menopausal women, while, with the 10 mcg dose, 
mean estradiol levels remained in the menopausal range 
indicating minimal estradiol absorption. After 1 year of treat-
ment with the 10 mcg vaginal tablet, levels of estrogen in the 
body were within the menopausal range (2.44–12.08 pg/mL). 
Overall, the profile of systemic exposure to estradiol was 
similar to the 25 mcg tablet, but absolute values were higher 
than with the lower dose tablet.
Although systemic absorption with local estrogen 
absorption is likely to be minimal, it is unknown whether 
this limited absorption will affect outcomes in women with 
hormone-dependent breast cancer. Currently, a clinical trial 
(N = 60) is underway to determine serum estradiol levels in 
menopausal women with breast cancer receiving adjuvant 
aromatase inhibitors (AIs) and low-dose vaginal estradiol 
tablet (10 mcg).16 The primary outcome is to determine the 
change in estradiol and follicle stimulating hormone (FSH) 
from baseline to 12 weeks in menopausal women receiving 
either letrozole or anastrozole treatment with vaginal estradiol 
(10 mcg). Secondary outcomes will describe the patterns of 
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estradiol and FSH levels over the 24-week study period; 
to compare the rise in estradiol   during treatment with the 
vaginal estradiol to see if there is a difference between AIs; 
and to compare the patients’ Female Sexual Function Index 
score and menopause quality of life questionnaire at baseline, 
week 12, and week 24. All in all, any rise above baseline 
serum estradiol may have an impact on AI efficacy.
In November 2009, the FDA approved the 10 mcg estra-
diol vaginal tablet formulation (Vagifem) for the treatment 
of VVA in menopausal women. Estradiol vaginal tablets 
previously were approved in a 25 mcg formulation in the 
United States and European Union. The company discon-
tinued the sale of Vagifem 25 mcg in the United States on 
July 30, 2010.17
Conclusion
Interest in the potential for lower systemic hormonal exposure 
with the use of local vaginal estrogen therapy has grown since 
the results of the Women’s Health Initiative were made public 
almost 10 years ago. When HT is considered solely for VVA, 
then local therapy is recommended. Vaginal administration 
of an ultra-low-dose estrogen provides   sufficient estrogen to 
relieve symptoms and reverse the atrophic changes associated 
with menopause, with the added benefit of limited systemic 
absorption.
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